May 2025 in “International Journal of Trichology” The supplement improved hair health and reduced shedding in people with telogen effluvium.
TrichoSol™ effectively stabilizes various hair treatment ingredients for different durations.
3 citations
,
September 2023 in “Advanced science” A new vaccine using a porous scaffold boosts immunity and protects against the flu better than traditional methods.
January 2026 in “JCEM Case Reports” A woman with hypothyroidism developed an allergy to IV levothyroxine after being resistant to oral forms.
October 2024 in “International Journal of Pharmaceutics” The finasteride patch effectively treats hair loss by enhancing skin absorption.
April 2022 in “Reactions Weekly”
2 citations
,
January 2019 in “Annals of dermatology/Annals of Dermatology” A patient experienced permanent hair loss due to an allergic reaction to a corticosteroid injection.
3 citations
,
July 2017 in “International journal of medicine” Intralesional triamcinolone acetonide effectively treats alopecia areata, as shown by significant improvements in hair regrowth and dermoscopic indicators.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
3 citations
,
November 2020 in “Dermatologic Therapy” Start with 2.5 mg/mL triamcinolone acetonide for scalp alopecia areata and increase if needed.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
1 citations
,
July 2020 in “Reviews in separation sciences” October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
Hair intradermotherapy effectively treats hair loss and boosts self-esteem.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
January 2020 in “International Journal of Research in Pharmacy and Chemistry” A reliable method was created to measure dutasteride and related molecules in capsules.
January 2025 in “TURKDERM” Alopecia areata incognito in children can be effectively treated with triamcinolone acetonide and supplements, leading to full hair regrowth.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
48 citations
,
January 2011 in “International journal of trichology” Intralesional triamcinolone acetonide is the most effective treatment for localized alopecia areata.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
1 citations
,
January 2007 in “The Kitakanto Medical Journal” Effective treatment for UFT overdose includes antibiotics and G-CSF, with bone marrow biopsy and transfusion as backup options.
July 2025 in “Journal of Cosmetic Dermatology” Triamcinolone is more effective than methotrexate for treating localized alopecia areata.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.